Chicken CD14, unlike mammalian CD14, is trans-membrane rather than GPI-anchored

Citation for published version:

Digital Object Identifier (DOI):
10.1016/j.dci.2008.07.008

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Developmental and Comparative Immunology

Publisher Rights Statement:
Copyright 2008 Elsevier Ltd

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Chicken CD14, unlike mammalian CD14, is trans-membrane rather than GPI-anchored

Zhiguang Wu*, Lisa Rothwell, Tuanjun Hu, Pete Kaiser

Institute for Animal Health, Compton, Berkshire RG20 7NN, UK

1. Introduction

CD14 is a myelomonocytic differentiation antigen in mammals [1]. Human CD14 is a single-copy gene encoding two protein forms: a 50–55-kDa glycosylphosphatidylinositol (GPI)-anchored membrane protein (mCD14) and a monocyte or liver-derived soluble serum protein (sCD14) that lacks the anchor [2–5]. CD14 is the lipopolysaccharide (LPS)-LPS binding protein (LBP) receptor, forming a multi-protein complex containing at least CD14, MD-2 and TLR4 [6–8]. The crucial role of CD14 in LPS signalling has been confirmed with knock-out mice; CD14-deficient mice are highly resistant to septic shock initiated by injection of either LPS or live bacteria [9–11]. Both mCD14 and sCD14 are critical for LPS-dependent signal transduction, and sCD14 confers LPS sensitivity to cells lacking mCD14. In addition to the LPS of Gram-negative bacteria, CD14 can bind other microbial products such as peptidoglycan (PGN) and lipoproteins [12].

CD14 was first identified on the surface of monocytes and macrophages [13] and ever since CD14 has been widely used as a monocyte/macrophage marker. Recently it has become clear that CD14 is also expressed by other cells and not even restricted to the myeloid cell lineage [14]. In mammals, CD14 has been well characterized [2,15–18] but this molecule has yet to be described in a non-mammalian species. In this study we report for the first time the identification and characterization of chicken CD14 (chCD14).

2. Materials and methods

2.1. Bioinformatic identification and cloning of chicken CD14

BLAST was used to search Ensembl and predict the cDNA sequence of the chicken homologue of the human myelomonocytic differentiation antigen, CD14, was cloned by RT-PCR from chicken bone marrow cell RNA, using oligonucleotide primers based on the predicted cDNA sequence. The cloned chicken CD14 (chCD14) cDNA encodes an open reading frame of 465 amino acids (aa), with 31–34% aa identity to mouse, bovine and human (hu) CD14. As in mouse and man, chCD14 is a leucine-rich protein. In mammals, CD14 is a GPI-anchored protein. Protein structure analysis suggested that chCD14, by contrast, was potentially a trans-membrane protein. The predicted aa sequence comprises an extracellular domain of 417 aa, followed by a 23-aa trans-membrane segment, and a 25-aa intracytoplasmic region, the latter containing no obvious signalling motifs. COS-7 cells were transfected with p3XFLAG-CMV™-8::chCD14 or pCDM8::huCD14, incubated with or without PI-PLC and stained with anti-FLAG or anti-huCD14 antibody respectively. PI-PLC cleaved huCD14 but not chCD14, suggesting that chCD14 is not GPI-anchored. Real-time quantitative RT-PCR analysis revealed that chCD14 mRNA was expressed in most lymphoid and non-lymphoid tissues, except muscle. ChCD14 mRNA was also expressed in most cells examined but strongly expressed in chicken peripheral blood monocyte/macrophages and KUL01+ splenocytes.
harvested and total RNA isolated using an RNeasy Mini kit (Qiagen, Crawley, UK), with on-column DNasel treatment. Separate RNA preparations were isolated from bone marrow from three different birds and RT-PCRs were carried out separately using the RNAs from these three preparations. First strand synthesis was for 50 min at 42 °C in a 20-μl volume containing 4 pmol of oligo-dt, 200 U Superscript II (Invitrogen, Paisley, UK) and 500 ng bone marrow RNA. After denaturation of the reverse transcriptase at 94 °C for 3 min, 2 μl of this reaction mix was added as template to a 20-μl PCR reaction, containing 20 pmol of each primer (CD14-1 and CD14-2), 0.4 mM dNTPs, 1 μl Taq polymerase and 4 μl Q solution (Qiagen). Cycling conditions were 30 cycles of 94 °C for 1 min, 58 °C for 1 min, 72 °C for 1 min. The PCR products were purified and primers CD14-3 and CD14-4 were used to reamplify and clone the entire coding sequence of chCD14 from the initiation to the stop codons inclusive. The resulting PCR product was ligated into TOPO pCR2.1 (Invitrogen) and the complete sequence of three clones determined on each strand. Based on the protein structure prediction, primers (CD14-5 and CD14-6) were designed to subclone the cDNA encoding the predicted mature protein of chCD14 into p3XFLAG-CMV™-G for eukaryotic expression. Several clones of this construct (p3XFLAG-CMV™-G:chCD14) were sequenced to confirm the integrity of the inserts. The cDNA sequence has been submitted to Ensembl with the accession number AM933191.

2.3. Total RNA isolation

RNA from the tissues and cells described above was extracted using an RNeasy Mini kit following the manufacturer’s instructions. To avoid contamination with genomic DNA, as CD14 is a single exon gene, the samples were exposed to an on-column treatment with RNase-free DNase I (Qiagen) for 60 min at room temperature (RT). The RNA was eluted in RNase-free water and stored at ~80 °C until required.

2.4. Real-time quantitative RT-PCR analysis of chCD14 mRNA expression

ChCD14 mRNA levels in different tissues and lymphoid cells were quantified using a well-described method (e.g.,[19,26–28]). Primers and probe were designed using the Primer Express software program (PE Applied Biosystems, Warrington, UK). Details are given in Table 1. All probes were labelled with the fluorescent reporter dye 5-carboxyfluorescein (FAM) at the 5’ end and the quencher N,N,N’,N’-tetramethyl-6-carboxyrhodamine (TAMRA) at the 3’ end.

Real-time quantitative RT-PCR was performed using the Reverse Transcription qPCR Master Mix RT-PCR kit (Eurogentec, Seraing, Belgium). Amplification and detection of specific products were performed using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems) with the following cycle profile: one cycle of 50 °C for 2 min, 95 °C for 30 min and 95 °C for 5 min, and 40 cycles of 94 °C for 20 s, 59 °C for 1 min. Quantification was based on the increased fluorescence detected due to hydrolysis of the target-specific probes by the 5’-exonuclease activity of the 5’FAM 3’TAMRA end. Results are expressed in terms of the threshold cycle value (Ct), the cycle at which the change in the reporter dye passes a significance threshold (ΔΔCt).

To account for variation in sampling and RNA preparation, the Ct values for CD14-specific product for each sample were standardised using the Ct value of 28S rRNA product for the same sample. To normalise RNA levels between samples within an experiment, the mean Ct value for 28S rRNA was calculated by pooling values from all samples in that experiment. Tube-to-tube variations in 28S rRNA Ct values about the experimental mean were calculated. The slope of the 28S rRNA log10 dilution series regression line was used to calculate differences in input total RNA. Using the slopes of the respective CD14 or 28S rRNA log10 dilution series regression lines, the difference in input total RNA, as represented by the 28S rRNA, was then used to adjust CD14-specific Ct values, as follows: corrected

<table>
<thead>
<tr>
<th>Primer/probe</th>
<th>Sequence (5′-3′)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD14-1</td>
<td>ACCGCCTCTCTCTCAGCTGGTCTC</td>
</tr>
<tr>
<td>CD14-2</td>
<td>GGACCAGGACACCTCTTACAGT</td>
</tr>
<tr>
<td>CD14-3</td>
<td>ATGCGTGCCGGGGCTCTG</td>
</tr>
<tr>
<td>CD14-4</td>
<td>TTAACAGGTCTGCTACGG</td>
</tr>
<tr>
<td>CD14-5</td>
<td>ACAAAGTGTCGGTCTCAGCCAC</td>
</tr>
<tr>
<td>CD14-6</td>
<td>TCTCTAGATACAGGCTTCCGGGAC</td>
</tr>
<tr>
<td>CD14 F</td>
<td>GGAGGACCTCAGGATCACCATGACAT</td>
</tr>
<tr>
<td>CD14 R</td>
<td>GGAGCATCAGGACAGAAAGA</td>
</tr>
<tr>
<td>CD14 probe</td>
<td>(FAM)-AATGATCTTCTGTGACTGCTGACACTGCAA-(TAMRA)</td>
</tr>
<tr>
<td>28S F</td>
<td>GGCAGAACGACAGAAGAACT</td>
</tr>
<tr>
<td>28S R</td>
<td>GAGCCAGTTAGTACCTGCTG</td>
</tr>
<tr>
<td>28S probe</td>
<td>(FAM)-AGAAGCCTACAGCTGCCACCAAC-(TAMRA)</td>
</tr>
</tbody>
</table>

* F, Taqman forward primer; R, Taqman reverse primer.
Ct value = Ct + (Nt – Ct) × S/S

where Ct = mean sample Ct,
Nt = experimental 28S mean, Ct = mean 28S of sample, S = CD14 slope, S = 28S slope. Results were then expressed as 40-Ct values.

2.5. Transient expression of chCD14 in COS-7 cells

COS-7 cells were routinely grown in DMEM (Invitrogen) containing 10% FCS (PAA Laboratories, Linz, Austria), 1% nonessential amino acids, 1% l-glutamine, and 1 μg/ml streptomycin at 37 °C in 5% CO2 and passaged using standard conditions [29].

Pre-warmed medium was added to each chamber of chamber slides (Lab-Tek Chamber Slide System, Nunc, VWR, Lutterworth, UK), 500 μl per well for 4-chamber slides. Trypsinised COS-7 cells were added to each well (1 × 10^5 cells/well), left at RT for 10 min to allow cells to settle and then returned to 37 °C for 18–24 h. Growth medium was aspirated and Hepes-buffered DMEM (HBD, 700 μl) containing 3 μg DNA (p3XFLAG-CMV™-8::chCD14 or pCDM8::huCD14 [30]), 25 μg chloroquine, and 600 μg/ml DEAE-dextran was added to the cells, which were then incubated for 4 h at 37 °C in 5% CO2. The transfection medium was then removed and cells washed once with PBS. HBD containing 10% DMSO was added for 2 min, removed, replaced with 700 μl of growth medium and incubated for 40–60 h. One chamber on each slide was washed twice with cold PBS and incubated with phosphatidylinositol-specific phospholipase C (PI-PLC) (1.0 μl, Invitrogen) at 4 °C for 30 min and the other three chambers were incubated with PBS only. Afterwards the whole slides were washed twice with cold PBS, fixed in acetone and incubated with PBS/1% BSA/0.01% NaNO3 for 1 h at RT in a humidified chamber. Mouse anti-chCD14, monoclonal (MAb 1B10, 1:100, Invitrogen) was used as primary antibody, followed by an appropriate secondary antibody (1:500, Vector). The chance of Fig. 1.

Z. Wu et al. / Developmental and Comparative Immunology 33 (2009) 97–104

99

Fig. 1. Nucleotide (nt) and deduced amino acid (aa) sequences of chCD14. Numbers to the left of each row refer to nt and aa position alternately. The putative signal peptide (aa 1–18) is shown in bold and the predicted trans-membrane region is underlined. The potential N-linked glycosylation sites (Asn-X-Thr/Ser) are in bold and underlined.
FLAG M2 monoclonal antibody (mAb) (Sigma–Aldrich) was applied to the chamber containing COS-7 cells transfected with p3XFLAG-CMV™:chCD14. Appropriately diluted mouse anti-human CD14 mAb (UCMH1) was added to the chambers containing COS-7 cells transfected with pcDNA3.1 and one chamber transfected with p3XFLAG-CMV™:chCD14. The slides were incubated at RT for 1 h and then washed with PBS/0.05% Tween 20. Alexa Fluor® 568 goat anti-mouse IgG (H + L) (Invitrogen) was then added for 1 h at RT. 4',6-Diamidino-2-phenylindole (DAPI, Sigma–Aldrich) was used to detect the nuclei. A microscope with UV light (Leica DM IRB) was used for imaging. Positively staining cells were easily identifiable as red-coloured cells and cell nuclei were blue.

Flow cytometry analysis was used to detect the expression of chCD14. Briefly, COS-7 cells were cultured in T75 flasks and transfected with p3XFLAG-CMV™:chCD14 or pcDNA3.1::huCD14. 48 h post-transfection, cells were trypsinised and divided into two aliquots. One aliquot of cells was incubated with PI-PLC (1.0 U/ml, Invitrogen) at 4°C for 30 min and the other with PBS only. Cells were then incubated with mouse anti-FLAG M2 mAb or anti-human CD14 mAb. FITC-labelled F(ab’)2 fragments of polyclonal goat anti-mouse immunoglobulins (DAKO, Ely, Cambridgeshire, UK) were used as secondary antibodies (Ab). For all the labelling steps, cells (0.5–1.0 × 10⁶ cells/ml) were incubated for 10 min at RT with appropriate dilutions of the primary or secondary Ab in U-bottomed 96-well microtiter plates with two washes between each step. PBS containing 1.0% BSA and 0.1% NaN₃ was used as dilution and washing buffer. After the final wash, cells analysed on a FACScalibur (BD Biosciences, Oxford, UK).

3. Results and discussion

3.1. Cloning and sequence analysis of chCD14 cDNA

In man, the CD14 gene is on chromosome 5 in a region which contains a cluster of genes that encode several myeloid-specific growth factor and receptor genes, including platelet-derived growth factor receptor (PDGFR), beta-2-adrenergic receptor (ADRB2R), endothelial cell growth factor (ECGF) [16] and heparin-binding...
growth factor (HBGF). In mouse, CD14 is encoded on mouse chromosome 18 which also contains at least five genes encoding receptors (PDGFR, ADRB2R, la-associated invariant chain (II), glucocorticoid receptor (Grl-1) and colony stimulating factor 1 receptor (CSF-1R or Fms)) [15]. Thus CD14 forms a conserved syntenic group with these growth factor and growth factor receptor genes. We used the huCD14 sequence to search the chicken genome in Ensembl (by BLAST) and predicted the cDNA sequence of the chicken homologue of huCD14. It is encoded on chicken chromosome 13, Contig158.29, alongside several receptor genes, such as Cadherin-related neuronal receptor (CNR, ENSGALG0000000760), ADRB2R (ENSGALG00000002808) and heparin-binding growth factor 1 precursor (HBGF, ENSGALG00000007343). This suggests that, as in mammals, CD14 and the growth factor and growth factor receptor genes show conservation of synteny in the chicken.

The Ensembl novel protein coding prediction ENSGALT00000034888 identifies part of chCD14, but incorrectly as part of a three-exon gene spanning contigs 158.26-29, and overlapping another novel protein coding prediction ENSGALT00000001235. However, the ab initio GenScan translation prediction GENS00000074788 actually correctly identifies chCD14, although of course it is not annotated as such.

RNA isolated from chicken bone marrow cells was used as a template to amplify chCD14 cDNA with primers CD14-1 and CD14-2 and nested primers CD14-3 and CD14-4. The PCR product was 1398 bp in length with a high-GC content (Fig. 1). The primary structure of the chCD14 protein was deduced from the cDNA and consists of 465 aa (Fig. 1). A potential signal peptide cleavage site was predicted in the aa sequence (SignalP 3.0 server) between residues 18 and 19. ChCD14 contains nineteen cysteine residues, eight of which are conserved between chicken and mammals. In mammalian CD14, there are four disulphide bridges between these eight conserved cysteines (as shown in Fig. 2), suggesting that chCD14 has a similar secondary structure. There are five potential N-linked glycosylation sites (Asn-X-Thr/Ser), two of which are conserved with mammalian CD14. Alignment of the aa sequences of chCD14 and mammalian CD14 (Fig. 2) reveals 31–34% aa identity. As shown in Fig. 2, chCD14 contains 12 leucine-rich repeats (LRR, LxxLxLxx) [31], as opposed to the 11 found in mammalian CD14 [15]. LRRs provide a structural framework for the formation of protein–protein interactions [31].

In mammals, CD14 is a glycosylphosphatidylinositol (GPI)-anchored protein [2]. These proteins lack a trans-membrane domain, have no cytoplasmic tail, and are, therefore, located exclusively on the extracellular side of the plasma membrane. GPI proteins have been found in a wide variety of eukaryotes, including mammals, chickens and fish. On average, ~0.5% of cellular proteins in eukaryotes are GPI-anchored [32]. Unlike in mammals, protein structure analysis suggests that chCD14 is not a GPI-anchored protein but a type I trans-membrane protein. The predicted aa sequence comprises an extracellular domain of 417 aa, followed by a 23-aa trans-membrane segment, and a 25-aa intracytoplasmic region. There are no obvious signalling motifs in the potential cytoplasmic tail, as assessed directly by eye and also by using the SCANSITE program (http://scansite.mit.edu/) [33].

3.2. Expression of chicken CD14 mRNA in different tissues and cell populations

Expression of chCD14 mRNA in lymphoid and non-lymphoid tissues and lymphoid cells was assessed by real-time quantitative
RT-PCR (Fig. 3). ChCD14 mRNA was constitutively expressed in all the lymphoid and non-lymphoid tissues tested except for muscle. ChCD14 was also expressed in splenocytes, bursal cells and, thymocytes. Expression was down-regulated in mitogen-stimulated splenocytes and bursal cells ($P < 0.05$) but expression was not significantly altered ($P > 0.05$) in mitogen-stimulated thymocytes. ChCD14 was highly expressed in monocyte-derived macrophages and blood monocytes. ChCD14 was also expressed in blood-derived heterophils.

ChCD14 mRNA was detected in all splenocyte subsets. The general distributions of CD14 mRNA that we found in chicken tissues and cells were in accordance with the expression patterns of CD14 mRNA in mammals [13,34,35]. However, KUL01" splenocytes showed high expression of chCD14, as did blood monocytes/macrophages, and LPS stimulation significantly ($P < 0.05$) up-regulated the expression of chCD14 in those cells. Up-regulated expression of CD14 mRNA by LPS stimulation is also seen in mammals [36].

3.3. Transient expression of chicken CD14 in COS cells

To detect if chCD14 is a GPI-anchored protein as it is in mammals, COS-7 cells were transfected with p3XFLAG-CMV™-8::chCD14 or pCDM8::huCD14, and incubated with or without PI-PLC, before staining with an anti-FLAG or anti-huCD14 mAb as appropriate. Fig. 4 clearly shows that COS-7 cells transfected with huCD14 stained with the anti-human CD14 mAb (Fig. 4E), and this staining was lost when the transfected cells were pre-treated with PI-PLC (Fig. 4F), which releases GPI-anchored proteins. In contrast, COS-7 cells transfected with FLAG-tagged chCD14 stained with the anti-FLAG mAb (Fig. 4B), and this staining was retained following PI-PLC pre-treatment (Fig. 4C), suggesting that chCD14 is not GPI-anchored. Fig. 5 shows FACS analysis of COS-7 cells transfected and treated as described previously. Without PI-PLC treatment, approximately 10% of COS-7 cells were positive for either huCD14 or chCD14. Following PI-PLC treatment, only 2.7% of COS-7 cells were positive for huCD14 but a similar proportion (9.3%) to non-treated cells were positive for chCD14. These results again suggest that chCD14 is not GPI-anchored.

Although there is broad species-overlapping reactivity of mAbs directed against CD14, anti-huCD14 mAbs (clones CAM36A, UCHM1, TÜK4 and M5E2) did not cross-react with chicken cells, as tested by Saalmuller et al. [37]. To confirm this lack of reported cross-reactivity, chCD14 was expressed in COS-7 cells and stained with an anti-huCD14 antibody (UCHM1) (Fig. 4G). There was no apparent cross-reactivity. Either the anti-huCD14 antibody does not cross-react with chCD14, or the binding affinity is low. We also used UCHM1 to stain chicken

![Fig. 4. Detection of chCD14 expressed by COS-7 cells. (A–C and G) COS-7 cells transfected with p3XFLAG-CMV™-8::chCD14. (A) Isotype control; (B) without PI-PLC incubation, stained with anti-FLAG mAb M2; (C) with PI-PLC incubation, stained with anti-FLAG mAb M2; (G) without PI-PLC incubation, stained with anti-huCD14 mAb UCMH1. (D–F) COS-7 cells transfected with pCDM8::huCD14. (D) isotype control; (E) without PI-PLC incubation, stained with anti-huCD14 mAb UCMH1; (F) with PI-PLC incubation, stained with anti-huCD14 mAb UCMH1.](image-url)
spleen cryo-sections, and again did not find any cross-reactivity (data not shown).

3.4. Summary

In summary, chCD14 was cloned and molecularly characterized. Analysis of chCD14 mRNA expression levels in chicken tissues and cells showed a higher expression in chicken blood-derived monocytes, monocyte-derived macrophages and KUL01+ splenocytes.

ChCD14 shares many structural features with mammalian CD14, including eight conserved cysteines with the potential to form four disulphide bridges, and eleven conserved LRRs (and an extra potential chicken-specific LRR). Unlike mammalian CD14, chCD14 appears to have trans-membrane and cytoplasmic domains, suggesting that it is not GPI-anchored. This has important implications for the role of CD14 in the chicken’s response to LPS. A GPI-anchored protein in general is more mobile in the cell membrane than one that is trans-membrane. In mammals, and presumably in the chicken, CD14 is a co-receptor for LPS with LBP, MD-2 and TLR4. The kinetics of such interactions, and therefore presumably the response to LPS, may well be compromised by chCD14 being trans-membrane. We have here provided evidence that chCD14 is not GPI-anchored and this may, in part, explain anecdotal reports that chicken cells respond less well to LPS than the equivalent mammalian cells.

Acknowledgements

This research was undertaken with the financial support of Intervet. The authors would like to thank Lai Shan Kwong (Institute for Animal Health, Compton, UK) for kindly providing the pCDM8::huCD14 plasmid, and Mike Kogut (USDA, College Station, Texas, USA) for providing the heterophil mRNA.

References


Hughes S, Poh TY, Bumstead N, Kaiser P. Re-evaluation of the chicken MIP family of chemokines and their receptors suggests that CCL5 is the prototypic MIP family chemokine, and that different species have developed different repertoires of both the CC chemokines and their receptors. Dev Comp Immunol 2007;31(1):72–86.


Tregaskes CA, Bumstead N, Davison TF, Young JR. Chicken B-cell marker chB6 (Bu-1) is a highly glycosylated protein of unique structure. Immunogenetics 1996;44(3):212–7.


